Industries > Pharma > World Biological Drugs Market 2013-2023

World Biological Drugs Market 2013-2023

PUBLISHED: 13 May 2013
PAGES: 358
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Biologics – discover and assess products with highest revenue potential

Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected products.

You see what shapes the biologics industry, discovering its commercial potential

Discover, then, what the future holds for biologics (biologicals). Read on to see features of the biopharma industry and discover what its future market could be worth.

Forecasts and other analyses show you trends and best prospects

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. There you assess quantitative and qualitative analysis, news, outlooks, and developments (R&D). You also gain 174 tables, 129 charts, and four research interviews.

Many opportunities remain for biological drugs, because of their increasing use. Our study shows you the most lucrative parts of that market, helping you stay ahead. Now see how you can benefit your research, analyses and decisions.

Finding data you need has just got easier. The following sections show how you benefit from our new analysis.

Discover sales predictions for the world biologics market and its submarkets

Along with revenue prediction for the overall world market for biological drugs, our work shows forecasts from 2013 to 2023 for individual submarkets:
• Protein therapeutics – with sub forecasts for insulins, other recombinant hormones, plasma and recombinant coagulating factors, interferons, and other agents
• Monoclonal antibodies (mAbs) – with sub forecasts for autoimmune, anticancer, and other agents
• Fusion proteins
• Cellular and regenerative medicines – with sub forecasts for tissue-engineered products, cellular therapies, and gene therapy.

Our report shows you revenue potentials of biopharmaceuticals, helping you find opportunities to develop your business.

Also our investigation discusses what stimulates and restrains sales of biotechnological medicines. There you explore that industry, seeing what products can achieve the most success.

Discover sales forecasts for prominent brands

Our new study forecasts revenues of 13 leading products, including these:
• Lantus
• Epogen
• Avonex
• NovoRapid
• Humira
• Remicade
• Rituxan
• Herceptin
• Avastin.

There you discover how high sales can go, to 2023, with individual forecasts. You see what's happening, understanding trends, competition, challenges, and opportunities.

The report also divides its overall world forecast into those for geographical regions.

Leading national markets – where will highest revenues and growth occur?

Developments worldwide will influence the biologicals market, especially rising demand in developed and developing countries. Find progress and opportunities there.

Our analyses show you individual revenue forecasts to 2023 for eleven national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries – Brazil, Russia, India, and China.

There you discover prospects and potential sales. You assess the biological drug industry's future – hear about developments and find their significance. In particular, drug launches will change medical prescribing from 2013 to 2023.

Research and development – you see trends and possibilities for new therapies

What about R&D – the pipeline for new drugs? You see trends for these agents:
• Insulins and other recombinant hormones
• Plasma and recombinant coagulating factors
• Interferons and other protein therapeutics
• Rheumatoid arthritis (RA), other autoimmune, and asthma mAbs
• Multiple sclerosis (MS), lupus, and psoriasis mAbs.

Our study also discusses these biotechnologies in development:
• Cancer (oncology) and cardiovascular mAbs
• Alzheimer's disease, ophthalmic, and anti-infective mAbs
• Fusion proteins
• Tissue-engineered products
• Cellular therapies
• Gene therapy.

R&D for biological drugs holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.

In particular, mAbs and fusion proteins hold potential, with more than 25 late-stage candidates and several emerging technologies.

Anyhow, for large companies and specialty pharma firms, there exist many therapeutic and commercial opportunities. Our study explains. See, then, what the future holds.

Leading companies and 2017 market value

From 2013, product launches there hold great potential for investment, uptake, and revenues. Our study predicts the world market for biologics will reach $178.4bn in 2017, with further growth to 2023. See how high revenues can go.

There you assess what biopharma technologies, products types, and companies hold most potential. Our analyses cover these and many other developers and producers:
• Roche
• Amgen
• Novo Nordisk
• AbbVie
• Johnson & Johnson.

In our report you find 284 organisations mentioned. Also, you read four interviews with other authorities. Find out what shapes the industry.

R&D for biologicals is strong, and from 2013 there will arise many opportunities. There are prospects for new drugs and overall sales growth. Our work shows the possibilities, helping you stay ahead.

Nine ways World Biological Drugs Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:
• Revenue to 2023 for the world biologics market – discover that industry's overall sales prospects
• Revenues to 2023 for 15 world-level submarkets – investigate the potential of its components, finding the most promising places for investments and revenues
• Prospects to 2023 for 13 leading products – see revenue forecasts for top brands
• Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia – discover the best regions and countries for revenues and potential growth
• Activities of leading companies – hear about participants' actions, capabilities, results, and outlooks
• Charting and discussions of R&D – explore progress in the biological drugs industry, finding technological, medical, and commercial possibilities
• Interviews with other experts on biologicals – discover what authorities in that field think, say, and do, helping you stay ahead
• Competition and opportunities – investigate what shapes that market's future, including ways to develop business
• Analysis of what stimulates and restrains the biopharma market – assess challenges and strengths, helping you compete and gain advantages.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.

Discover potential now in the biologics market and find what you can gain.

For biologics, see commercial prospects from 2013 by ordering now

Our investigation is for everyone analysing the industry and market for biological drugs. There you find data, trends, opportunities, and predictions. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for World Biological Drugs Market 2013-2023


Download sample pages

Complete the form below to download your free sample pages for World Biological Drugs Market 2013-2023


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories